Ardelyx, Inc. (ARDX) SEC Filings & Earnings Calls

Commercial leadership gap could affect product launches and revenue growth.

“CCO resignation with no immediate replacement announced.”

ESRD PPS inclusion impact on XPHOZAH revenue growth

“XPHOZAH became part of the ESRD PPS on January 1, 2025, which means coverage for XPHOZAH for Medicare beneficiaries is not available under Medicare Part D; this resulted in a negative and material impact on our XPHOZAH revenue in 2025; and the continued lack of Medicare Part D coverage for XPHOZAH will result in a materially lower pace of revenue growth as c”

Legal challenge to CMS rule dismissed; no further litigation

“On June 26, 2026, the United States Court of Appeals affirmed the District Court’s dismissal. We are not pursuing further litigation on this matter.” · word for word

Dependence on single-source suppliers for manufacturing

“We rely completely on third parties, including certain single-source suppliers, to manufacture IBSRELA and XPHOZAH.” · word for word

IBSRELA revenue below expectations due to increased payor utilization management; guidance cut

“The demand for IBSRELA was strong despite revenues below our expectations resulting from significantly increased utilization management processes from payors” · word for word

CMS lawsuit dismissed; no further litigation on XPHOZAH reimbursement classification

“U.S. Court of Appeals affirmed dismissal of lawsuit against CMS related to XPHOZAH reimbursement classification; we will not pursue further litigation”

XPHOZAH long-term guidance pulled due to evolving market dynamics

“XPHOZAH long-term guidance is being pulled as the Company assesses evolving market dynamics and growth rates” · word for word

Increased leverage; loan secured by cash; floating rate exposes to interest rate risk.

“Loan Agreement contains customary events of default... secured by the Company’s cash... interest rate of the sum of 4.55% plus the greater of (a) the 1-month SOFR reference rate or (b) 3.5%.” · word for word

Guidance reliance on single product IBSRELA; pipeline execution risk.

“IBSRELA is cornerstone; blockbuster target by 2029.”

ESRD PPS revenue impact

“XPHOZAH became part of the ESRD PPS on January 1, 2025, which means coverage for XPHOZAH for Medicare beneficiaries is no longer available under Medicare Part D; this resulted in a negative and material impact on our XPHOZAH revenue in 2025; and the continued lack of Medicare Part D coverage for XPHOZAH will result in a materially lower pace of revenue growt” · word for word

Single-source supplier dependency

“We rely completely on third parties, including certain single-source suppliers, to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, ” · word for word

Debt covenant restrictions

“Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with SLR, as amended, and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.” · word for word

Dependence on IBSRELA for majority of revenue growth

“IBSRELA represents 67% of total revenue; guidance implies continued reliance”

Pipeline programs still in early stages with regulatory and clinical risks

“Phase 3 CIC trial enrollment to complete end of 2026; NHE3 program in pre-clinical”

Medicare Reimbursement Loss

“The change in Medicare reimbursement coverage had a negative and material impact on our XPHOZAH revenue in 2025.” · word for word

Single-Source Manufacturing

“Many of our CMOs are currently single source manufacturers.” · word for word

Drug Pricing Regulation

“If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government... based on most favored nation pricing.” · word for word

Accumulated Losses

“As of December 31, 2025, we had an accumulated deficit of $946.9 million.” · word for word

Preliminary results subject to audit adjustment

“These amounts are preliminary and are subject to adjustment in connection with preparation of audited financial statements” · word for word

Loss of key legal and medical leadership may disrupt operations and regulatory strategy.

“Elizabeth Grammer informed ... of her resignation; Edward Conner ... resigned as Chief Medical Officer”

XPHOZAH revenue declined YoY due to Medicare Part D transition; reliance on IBSRELA for growth; SG&A expenses high relative to revenue.

“XPHOZAH revenue was $27.4 million, compared to $51.5 million during the same period of 2024. The year-over-year decline in revenue is due to the loss of Part D coverage for Medicare patients.” · word for word

Reimbursement Risk

“The inclusion of XPHOZAH in the ESRD PPS creates additional uncertainty as to the commercial opportunity for XPHOZAH.” · word for word

Revenue Concentration Risk

“We are substantially dependent on the successful commercialization of IBSRELA, and there is no guarantee that we will maintain sufficient market acceptance for IBSRELA.” · word for word